As shown in Fig. 2A, plasma versican levels in the NSCLC group were greater than those in the benign disease and healthy control groups, and the difference was statistically significant (one-way ANOVA, F = 8.592, P < 0.001). Here, VCAN is linked to non-small cell lung carcinoma.